Pringsheim T, Day GS, Smith DB, Rae-Grant A, Licking N, Armstrong MJ, de Bie RMA, Roze E, Miyasaki JM, Hauser RA, Espay AJ, Martello JP, Gurwell JA, Billinghurst L, Sullivan K, Fitts MS, Cothros N, Hall DA, Rafferty M, Hagerbrant L, Hastings T, O’Brien MD, Silsbee H, Gronseth G, Lang AE (2021) Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN guideline subcommittee. Neurology 97:942–957

PubMed  PubMed Central  Google Scholar 

Jenner P, Rocha JF, Ferreira JJ, Rascol O, Soares-da-Silva P (2021) Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone. Expert Rev Neurother 21:1019–1033

CAS  PubMed  Google Scholar 

Stocchi F, Jenner P, Obeso JA (2010) When do levodopa motor fluctuations first appear in Parkinson’s disease? Eur Neurol 63:257–266

CAS  PubMed  Google Scholar 

Stocchi F, Antonini A, Barone P, Tinazzi M, Zappia M, Onofrj M, Ruggieri S, Morgante L, Bonuccelli U, Lopiano L, Pramstaller P, Albanese A, Attar M, Posocco V, Colombo D, Abbruzzese G, group Ds (2014) Early DEtection of wEaring off in Parkinson disease: the DEEP study. Parkinsonism Relat Disord 20:204–211

CAS  PubMed  Google Scholar 

Olanow CW, Kieburtz K, Rascol O, Poewe W, Schapira AH, Emre M, Nissinen H, Leinonen M, Stocchi F, Stalevo Reduction in Dyskinesia Evaluation in Parkinson’s Disease I (2013) Factors predictive of the development of Levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28:1064–1071

CAS  Google Scholar 

Colombo D, Abbruzzese G, Antonini A, Barone P, Bellia G, Franconi F, Simoni L, Attar M, Zagni E, Haggiag S, Stocchi F (2015) The “gender factor” in wearing-off among patients with Parkinson’s disease: a post hoc analysis of DEEP study. ScientificWorldJournal 2015:787451

PubMed  PubMed Central  Google Scholar 

Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323:548–560

PubMed  Google Scholar 

Grosset KA, Bone I, Grosset DG (2005) Suboptimal medication adherence in Parkinson’s disease. Mov Disord 20:1502–1507

PubMed  Google Scholar 

Grosset D, Antonini A, Canesi M, Pezzoli G, Lees A, Shaw K, Cubo E, Martinez-Martin P, Rascol O, Negre-Pages L, Senard A, Schwarz J, Strecker K, Reichmann H, Storch A, Löhle M, Stocchi F, Grosset K (2009) Adherence to antiparkinson medication in a multicenter European study. Mov Disord Off J Mov Disord Soc 24:826–832

Google Scholar 

Fox SH, Katzenschlager R, Lim SY, Barton B, de Bie RMA, Seppi K, Coelho M, Sampaio C, Movement Disorder Society Evidence-Based Medicine C (2018) International Parkinson and movement disorder society evidence-based medicine review: Update on treatments for the motor symptoms of Parkinson’s disease. Mov Disord 33:1248–1266

CAS  PubMed  Google Scholar 

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P, Bi-Park i, (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154–165

CAS  PubMed  Google Scholar 

Lees AJ, Ferreira J, Rascol O, Poewe W, Rocha JF, McCrory M, Soares-da-Silva P, Investigators B-S (2017) Opicapone as Adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74:197–206

PubMed  Google Scholar 

Ferreira JJ, Lees A, Rocha JF, Poewe W, Rascol O, Soares-da-Silva P (2019) Long-term efficacy of opicapone in fluctuating Parkinson’s disease patients: a pooled analysis of data from two phase 3 clinical trials and their open-label extensions. Eur J Neurol 26:953–960

CAS  PubMed  Google Scholar 

Rocha JF, Ebersbach G, Lees A, Tolosa E, Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Magalhaes D, Gama H, Soares-da-Silva P (2021) The added benefit of opicapone when used early in Parkinson’s disease patients with levodopa-induced motor fluctuations: a post-hoc analysis of BIPARK-I and -II. Front Neurol 12:754016

PubMed  PubMed Central  Google Scholar 

Lee JY, Ma HI, Ferreira JJ, Rocha JF, Sung YH, Song IU, Ahn TB, Kwon DY, Cheon SM, Kim JM, Lee CS, Lee PH, Park JH, Lee JH, Park MY, Kim SJ, Baik JS, Choi SM, Shin HW, Lee HW, Kang SY, Jeon B (2024) Opicapone to treat early wearing-off in Parkinson’s disease patients: the Korean ADOPTION trial. Mov Disord Clin Pract 11:655–665

PubMed  PubMed Central  Google Scholar 

Hauser RA, Friedlander J, Zesiewicz TA, Adler CH, Seeberger LC, O’Brien CF, Molho ES, Factor SA (2000) A home diary to assess functional status in patients with Parkinson’s disease with motor fluctuations and dyskinesia. Clin Neuropharmacol 23:75–81

CAS  PubMed  Google Scholar 

Park J, Koh SB, Kwon KY, Kim SJ, Kim JW, Kim JS, Park KW, Paik JS, Sohn YH, Ahn JY, Oh E, Youn J, Lee JY, Lee PH, Jang W, Kim HJ, Jeon BS, Chung SJ, Cho JW, Cheon SM, Kang SY, Park MY, Park S, Huh YE, Kang SJ, Kim HT (2020) Validation study of the official korean version of the movement disorder society-unified Parkinson’s disease rating scale. J Clin Neurol 16:633–645

PubMed  PubMed Central  Google Scholar 

Goetz CG, Tilley BC, Shaftman SR, Stebbins GT, Fahn S, Martinez-Martin P, Poewe W, Sampaio C, Stern MB, Dodel R, Dubois B, Holloway R, Jankovic J, Kulisevsky J, Lang AE, Lees A, Leurgans S, LeWitt PA, Nyenhuis D, Olanow CW, Rascol O, Schrag A, Teresi JA, van Hilten JJ, LaPelle N, Movement Disorder Society URTF (2008) Movement disorder society-sponsored revision of the unified parkinson’s disease rating scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord 23:2129–2170

PubMed  Google Scholar 

Jenkinson C, Fitzpatrick R, Peto V, Greenhall R, Hyman N (1997) The PDQ-8: development and validation of a short-form parkinson’s disease questionnaire. Psychol Health 12:805–814

Google Scholar 

Schade S, Mollenhauer B, Trenkwalder C (2020) Levodopa equivalent dose conversion Factors: An Updated Proposal Including Opicapone and Safinamide. Mov Disord Clin Pract 7:343–345

PubMed  PubMed Central  Google Scholar 

Hauser RA, Gordon MF, Mizuno Y, Poewe W, Barone P, Schapira AH, Rascol O, Debieuvre C, Frassdorf M (2014) Minimal clinically important difference in Parkinson’s disease as assessed in pivotal trials of pramipexole extended release. Parkinsons Dis 2014:467131

PubMed  PubMed Central  Google Scholar 

Ferreira JJ, Rascol O, Stocchi F, Antonini A, Moreira J, Castilla-Fernandez G, Rocha JF, Holenz J, Poewe W (2023) Opicapone as adjunctive to levodopa-treated Parkinson's disease patients without motor complications: preliminary data from the EPSILON Study [Abstract]. https://www.mdscongress.org/IC23-Late-BreakingAbstractBooklet.pdf.

Ferreira JJ, Poewe W, Rascol O, Stocchi F, Antonini A, Moreira J, Guimaraes B, Rocha JF, Soares-da-Silva P (2022) Effect of opicapone on levodopa pharmacokinetics in patients with fluctuating Parkinson’s disease. Mov Disord 37:2272–2283

CAS  PubMed  PubMed Central  Google Scholar